Tag Archive for: cgt

Resolution Therapeutics Announces Regenerative Macrophage Therapy (RMT) Manufacturing Process & Candidate Testing Suite at ASGCT 2025

/in

– Proprietary manufacturing process enables robust and scalable GMP-compliant manufacture of autologous engineered RMT products, including lead asset RTX001 in end-stage liver disease (ESLD). – Novel mode of action-based candidate testing suite enabled the discovery of RTX001, which shows enhanced anti-inflammatory and anti-fibrotic effects in vitro and in vivo. – The EMERALD Phase1/2 interventional study […]

Read more

European Commission Grants Orphan Drug Designation for Vivet Therapeutics Gene Therapy Product for the Treatment of Cerebrotendinous Xanthomatosis (CTX)

/in

Pre-clinical data of VTX-806 in mice demonstrated normalization of metabolic parameters in blood and brain, and of upregulated compensatory enzymes EUR 4.9 million funding provided by French Government to develop VTX-806 as an effective treatment option to stabilize or reverse symptoms in CTX patients Paris, France, September 5, 2024 – Vivet Therapeutics (“Vivet”), a clinical […]

Read more

Vivet Therapeutics presents interim data on its Phase 1/2 GATEWAY trial for the Treatment of Wilson Disease at EASL Congress 2024

/in

VTX-801 increased ceruloplasmin ferroxidase activity and improved liver histology Encouraging safety and tolerability with no serious adverse events reported Paris, France, June 5, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders, today announces the presentation of interim data on its international Phase […]

Read more

Study on Treatment of Wilson Disease in Japan Published in Japanese Journal of Gastroenterology and Hepatology

/in

Paris, France, May 30, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders, today announces the publication of a peer reviewed paper titled ‘Treatment of Wilson Disease in Japan: An Insurance Claims Database Study’ in the Japanese Journal of Gastroenterology and Hepatology. Wilson […]

Read more

Highly experienced CDMO expert Michel Spagnol appointed Chairman of Astraveus

/in

Paris, France, 28 November, 2023 – Astraveus SAS (“Astraveus” or the “Company”), the creator of modular, microfluidic cell foundries that transform cell and gene therapy (CGT) manufacturing, today announces the appointment of Michel Spagnol as its new Chairman of the Board. Michel joins existing Board members Jérémie Laurent, CEO; Alain Huriez, Director; AdBio Partners; Christian […]

Read more